The Department of Defense (DoD) has awarded Weill Cornell Medicine a substantial $2.5 million grant to develop innovative therapies for triple-negative breast cancer, a highly aggressive and treatment-resistant form of the disease. This funding is a testament to the institution's cutting-edge research and its potential to revolutionize patient care.
Triple-negative breast cancer is particularly challenging to treat due to its lack of specific protein targets, often leaving patients with limited treatment options beyond chemotherapy. However, Weill Cornell's research team, led by Professor Xiaojing Ma and Professor Gang Lin, is making significant strides in this field.
The focus of their research is the UBR5 protein, which is overproduced in aggressive breast cancers and other difficult-to-treat malignancies. By targeting UBR5, the team aims to interfere with multiple cancer-promoting mechanisms, offering a novel approach to cancer treatment.
Ma's lab has previously demonstrated the functional requirement of UBR5 in tumor growth and metastasis through preclinical models. This groundbreaking research, published in a highly cited 2017 paper, provided the impetus for developing drugs that target UBR5. Ma and Lin, a medicinal chemist, are now working together to design small molecule drugs and protein degraders that can selectively target cancer cells while minimizing side effects.
The team has already identified compounds that inhibit UBR5 at high concentrations, providing a proof-of-concept for their approach. However, they acknowledge that achieving an effective dose on-target requires high concentrations that may induce side effects. This grant will enable them to refine the inhibitors, making them effective at much lower concentrations.
The ultimate goal is to evaluate the drugs' efficacy against breast cancer in laboratory models that closely mimic human cancers. Success in this project could pave the way for a new generation of targeted therapies not only for triple-negative breast cancer but also for other aggressive cancers, such as ovarian, pancreatic, and prostate cancers, where UBR5 is also overproduced.
This research highlights the potential of precision medicine in cancer treatment, offering a glimmer of hope for patients with limited treatment options. As the team continues to make strides in this field, the future of cancer treatment may be transformed, providing more effective and targeted therapies for patients worldwide.
